Advertisement
Advertisement
Sitagliptin Sandoz

Sitagliptin Sandoz

sitagliptin

Manufacturer:

Sandoz

Distributor:

Zuellig Pharma

Marketer:

Sandoz
Concise Prescribing Info
Contents
Sitagliptin
Indications/Uses
Adjunct to diet & exercise to improve glycemic control in patients w/ type 2 DM as monotherapy, or in combination w/ metformin, sulphonylurea, or PPARγ agonist (ie, thiazolidinedione) as initial therapy, or combination w/ metformin & sulphonylurea, or metformin & PPARγ agonist (ie, thiazolidinedione), when single agent alone or dual therapy, w/ diet & exercise, does not provide adequate glycemic control. Adjunct to diet & exercise to improve glycemic control in combination w/ insulin (w/ or w/o metformin).
Dosage/Direction for Use
Monotherapy or combination therapy w/ metformin, sulfonylurea, insulin (w/ or w/o metformin), PPARγ agonist (eg, thiazolidinediones), metformin + sulfonylurea or metformin + PPARγ agonist 100 mg once daily. Moderate renal impairment (GFR ≥30 to <45 mL/min/1.73 m2) 50 mg once daily. Severe renal impairment (GFR ≥15 to <30 mL/min/1.73 m2) or ESRD (GFR <15 mL/min/1.73 m2) including those requiring hemodialysis or peritoneal dialysis 25 mg once daily. May be administered w/o regards to timing of dialysis.
Administration
May be taken with or without food.
Special Precautions
Discontinue use if hypersensitivity reactions, pancreatitis or bullous pemphigoid is suspected. Not to restart treatment if acute pancreatitis is confirmed. Not to be used in patients w/ type 1 diabetes or for treatment of diabetic ketoacidosis. Anaphylaxis, angioedema, & exfoliative skin conditions including SJS. Acute pancreatitis, persistent, severe abdominal pain; necrotising or haemorrhagic pancreatitis. Hypoglycaemia in combination w/ insulin or sulphonylurea. Dizziness & somnolence. Patients w/ history of pancreatitis. Assess renal function prior to initiation of therapy & periodically thereafter. May affect ability to drive & use machines. Severe hepatic impairment (Child-Pugh score >9). Not to be used during pregnancy & lactation. Not to be used in childn & adolescents 10-17 yr. Childn <10 yr.
Adverse Reactions
Hypoglycemia. Monotherapy: Headache. Combination therapy: Flu, nausea & vomiting, flatulence, constipation, peripheral oedema.
Drug Interactions
Altered pharmacokinetics w/ potent CYP3A4 inhibitors (ie, ketoconazole, itraconazole, ritonavir, clarithromycin) in patients w/ severe renal impairment or ESRD. Increased AUC & Cmax of digoxin.
MIMS Class
Antidiabetic Agents
ATC Classification
A10BH01 - sitagliptin ; Belongs to the class of dipeptidyl peptidase 4 (DPP-4) inhibitors. Used in the treatment of diabetes.
Presentation/Packing
Form
Sitagliptin Sandoz FC tab 100 mg
Packing/Price
4 × 7's
Form
Sitagliptin Sandoz FC tab 50 mg
Packing/Price
4 × 7's
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement